Generate Biomedicines (NASDAQ:GENB) Shares Gap Up – Here’s What Happened

Shares of Generate Biomedicines Inc (NASDAQ:GENB) gapped up prior to trading on Wednesday. The stock had previously closed at $12.26, but opened at $12.61. Generate Biomedicines shares last traded at $12.5120, with a volume of 796,486 shares trading hands.

Analyst Ratings Changes

Several research firms have issued reports on GENB. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Generate Biomedicines in a research note on Monday, October 5th. Weiss Ratings raised shares of Generate Biomedicines from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, September 25th. Finally, Wall Street Zen raised shares of Generate Biomedicines from a “sell” rating to a “hold” rating in a research report on Saturday, September 26th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $26.40.

Generate Biomedicines Stock Up 0.7%

The firm has a fifty day moving average price of $15.52 and a 200-day moving average price of $14.43. The firm has a market cap of $1.59 billion and a price-to-earnings ratio of -7.77.

Generate Biomedicines (NASDAQ:GENB) last released its earnings results on Thursday, August 6th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The company had revenue of $6.31 million during the quarter. Equities research analysts anticipate that Generate Biomedicines Inc will post -2.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Susquehanna International Group LLP acquired a new position in shares of Generate Biomedicines in the 2nd quarter valued at $196,000. AXQ Capital LP acquired a new stake in shares of Generate Biomedicines in the second quarter valued at about $218,000. Squarepoint Ops LLC purchased a new stake in shares of Generate Biomedicines during the second quarter valued at approximately $530,000. Bank of New York Mellon Corp purchased a new position in Generate Biomedicines in the 2nd quarter valued at about $967,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Generate Biomedicines during the 2nd quarter valued at approximately $1,431,000.

About Generate Biomedicines

Generate Biomedicines is a biotechnology company focused on discovering and developing protein-based medicines. The company uses generative artificial intelligence, machine learning and laboratory-based biological research to design new therapeutic proteins and identify candidates with potential applications in a range of diseases.

Its platform, often described as a generative biology approach, is designed to model biological systems and create proteins with desired characteristics rather than relying solely on modifying naturally occurring molecules.